Lack of association between hyperprolactinemia and soluble IL-2 receptor levels in systemic lupus erythematosus

Lupus

Volumn 12, Issue 2, 2003, Pages 107-111

  Daza, L ^a,e   Lavalle, C ^b   Duarte, C ^c   Huerta, R ^d   Moreno, J ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b LIVER RESEARCH UNIT   (Mexico)

^c SECRETARÍA DE SALUD   (Mexico)

^d UNIVERSITY OF GUANAJUATO   (Mexico)

^e Rheumatology Department   (Mexico)

Author keywords

Hyperprolactinemia; Immunoglobulin G; Soluble IL 2 receptor; Systemic lupus erythematosus

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 2 RECEPTOR; PREDNISONE; PROLACTIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD DONOR; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERPROLACTINEMIA; IMMUNOGLOBULIN BLOOD LEVEL; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; FEMALE; HUMANS; HYPERPROLACTINEMIA; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES;

EID: 0037286991     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203303lu327oa     Document Type: Article

References (35)

1. Jonsson H, Nivel O, Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine 1989; 68: 141-150.
2. Stem R, Fishman J, Brusman H, Kunkel H. Systemic lupus erythematosus assocciated with klinefelter's syndrome. Arthritis Rheum 1979; 22: 1195-1198.
3. Lahita R, Bradlow H, Kunkel H, Fishman J. Alterations of estrogen metabolism in systemic lupus erythematosus. Arthritis Rheum 1979; 22: 1195-1198.
4. Amano H, Morimoto S, Kaneko H, Tokano Y, Takasi Y, Hashimoto H. Effect of intravenous cyclophosphamide in systemic lupus erythematosus: relation to lymphocyte subsets and activation markers. Lupus 2000; 9: 478.
5. Yu DT, Clements PJ, Paulus HE, Peter JB, Levy J. Human lymphocyte subpopulations. Effect of corticosteroids. J Clin Invest 1974; 53: 565-571.
6. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function and clinical application. Ann Intern Med 1990; 113: 619-627.
7. Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell 1993; 73: 5-8.
8. Cohen N, Stempel C, Colombe B et al. Soluble interleukin-2 receptor: detection and potential role in organ transplantation. Clin Immunol 1990; 10: 175, 182-186.
9. Clemens PhJ, Peter JB, Agopian MS et al. Elevated serum levels of soluble interleukin-2 receptor, interleukin-2 and neopterin in diffuse and limited scleroderma: effect of chlorambucil. J Rheumatol 1990; 17: 908-910.
10. Laut J, Senitzer, Petrucci R et al. Soluble interleukin-2 receptors in lupus nephritis. Clin Nephrol 1992; 38: 179-184.
11. Wolf RE, Brelsford W. Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum 1988; 31: 729-735.
12. Tokano Y, Murashima A, Takasaki Y, Hashimoto H, Okumura K, Hirose SH. Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus. Ann Rheum Dis 1989; 48: 803-809.
13. Nagy E, Berczi I. Immunodeficiency in hipophysectomized rats. Acta Endocrinol 1979; 89: 530-537.
14. Gala RR, Shevach EM. Identification by analytical flow cytometry of prolactin receptors on immunocompetent cell populations in the mouse. Endocrinology 1993; 133: 1617-1623.
15. Gagnerault MC, Touraine P, Savino W, Kelly PA, Dardenne M. Expression of prolactin receptors in murine lymphoid cells in normal and autoimmune situations. J Immunol 1993; 150: 5673-5681.
16. O'Neal KD, Schwarz LA, Yu-lee L-Y. Prolactin receptor gene expression in lymphoid cells. Mol Cell Endocrinol 1991; 82: 127-135.
17. Dardenne M, Leite de Moraes M, Kelly PA, Gagnerault M-C. Prolactin receptor expression in human hematopoietic tissues analysed by flow cytometry. Endocrinology 1994; 134: 2108-2114.
18. Cabharwal P, Glaser R, Lafuse W et al. Prolactin synthesized and secreted by human peripheral blood mononuclear cells: an autocrine growth factor for lymphoproliferation. Proc Natl Acad Sci USA 1992; 89: 7713-7716.
19. Montgomery DW, Zukoski CF, Shah GN, Buckley AR, Pacholczyk T, Russell DH. Concavalin A-stimulated murine splenocytes produce a factor with prolactin-like bioactivity and immunoreactivity. Biochem Biophys Res Commun 1987; 145: 692-698.
20. Larrea F, Martinez-Castillo A, Cabrera V et al. A bioactive 60-Kilodalton prolactin species is preferentially secreted in cultures of mitogen-stimulated and nonstimulated peripheral blood mononuclear cells from subjects with systemic lupus erythematosus. J Clin Endocrinol Metabol 1997; 82: 3664-3669.
21. Gutierrez MA, Molina JF, Jara LJ et al. Prolactin and systemic lupus erythematosus: prolactin secretion by SLE lymphocytes and proliferation (autocrine) activity. Lupus 1995; 4: 348-352.
22. Mukherjee P, Mastro AM, Hymer WC. Prolactin induction of interleukin-2 receptors on rat splenic lymphocytes. Endocrinology 1990; 126: 88-94.
23. Clevenger CV, Russell DH, Appasamy PM, Prystowsky MM. Regulation of interleukin 2-driven T-lymphocyte proliferation by prolactin. Proc Natl Acad Sci USA 1990; 87: 6460-6464.
24. Longhi SA, Miranda ME, Gobet MG, Retegui LA. A monoclonal antibody recognizing an epitope shared by receptors for growth hormone, prolactin, interleukin 2 and interleukin 6. Mol Cell Biochem 1999; 195: 235-243.
25. Lavalle C, Loyo E, Paniagua R et al. Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus. J Rheumatol 1987; 14: 268-272.
26. Jara LJ, Graef A, Lavalle C. Prolactin and gonadal hormones during pregnancy in systemic lupus erythematosus. J Rheumatol 1990; 17: 1569-1570.
27. Folomeev M, Prokaeva T, Nassonova V et al. Prolactin levels in men with systemic lupus erythematosus and RA. J Rheumatol 1990; 17: 1569-1570.
28. Jara LJ, Sanchez C, Silveira L et al. Hyperprolactinemia in systemic lupus erythematosus: association with disease activity. Am J Med Sci 1992; 302: 222-226.
29. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
30. Bombardier C, Gladman D, Urowitz M. Derivation of the SLEDAI. Arthritis Rheum 1992; 35: 631-640.
31. Elboume KB, Keisler D, McMurray. Differential effects of estrogen and prolactin on autoimmune disease in the NZB/NZW F1 mouse model of systemic lupus erythematosus. Lupus 1998; 7: 420-427.
32. Horseman N, Zhao W, Montecino-Rodriguez E, Tanaka M et al. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J 1997; 16: 6926-6935.
33. Freeman ME, Kanyicska BL, Lerant A et al. Prolactin: structure, function and regulation of secretion. Physiol Rev 2000; 80: 1523-1631.
34. Gutierrez MA, Molina JF, Jara LJ et al. Prolactin-induced immunoglobulin and autoantibody production by peripheral blood mononuclear cells from systemic lupus erythematosus and normal individuals. Int Arch Allergy Immunol 1996; 109: 229-235.
35. Gabay C, Cakir N, Moral F et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. JRheumatol 1997; 24: 303-308.